Details

Created: 12 November 2008

As part of our proteomic studies and research collaborations, we have generated and thoroughly characterized a number of antibodies against membrane proteins and associated partners. A selected set – mostly affinity-purified polyclonal antibodies – will soon become commercially available by the end of 2008. Our antibodies are unique with respect to their quality and level of validation: specified applications like Westernblots, immunohistochemistry and affinity purification have been tested using native source-derived sample specimens, stringent controls including knockout samples or independent antibodies and quantitative mass spectrometry.

Details

Created: 12 May 2008

To meet the increasing needs in bioinformatic processing of mass spectrometry data and to make full use of our proteomic capabilities, the company has decided to focus R&D efforts on development of novel tools for quantification and database integration. The new quantification software shall overcome current limitations of available tools and deliver reliable label-free protein quantification with high sensitivity and over a broad dynamic range. In a first step, it is planned to build a stand-alone version for evaluation of LC-MS/MS data from linear ion trap instruments. It will subsequently be developed into a commercial product and used to build up a proprietary membrane protein interaction database.

Details

Created: 08 January 2007

Read more: Ionenkanal-Superkomplexe - neue Proteinmaschinen der Neurobiologie